Obulytix
Obulytix is a biotech company in Ghent, Belgium, founded in 2023. It has 1 recorded funding round, most recently a Seed in December 2023.
Building the future of antibiotics
- Headquarters
- Ghent
- Founded
- 2023
- Business Model
- B2B
- Website
- obulytix.com
- Last Round
- SeedDec 2023
- Rounds
- 1
Indexed holds 1 funding round and 1 investor for this company. The full record is or through the API.
About
Obulytix is a Belgium-based preclinical biotech, founded in 2023 as a spin-off from Ghent University and KU Leuven, that develops Precision Lysin Therapeutics as next-generation antibiotics. The company engineers phage-derived lysins—enzymes that cleave bacterial cell walls with high specificity—to treat multidrug-resistant Gram-negative infections and antimicrobial resistance, including infection control in cancer care. It is backed by Boehringer Ingelheim Venture Fund, Qbic Fund, and Gemma-Frisius Fund.
Summary
Its most recent funding was a Seed round in Dec 2023. Investors include Boehringer Ingelheim Venture Fund.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2023
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/obulytix"><img src="https://indexed.vc/api/badge/company/obulytix" alt="Obulytix on Indexed.vc" width="260" height="76" /></a>